Which Tyrosine Kinase Inhibitor Must We Apply Before? A Case Report of Crizotinib-resistant Patient with Concomitant EGFR and EML4-ALK Gene Mutations
West Indian med. j; 69 (3), 2021
ABSTRACT The concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocations in lung adenocancers are very rare scenarios. Until now, 42 cases described in the literature have all been treated by different drugs. There is no overall consensus regarding the...
Adenocarcinoma/genética, Neoplasias Pulmonares/genética, Mutación/genética, Genes erbB-1/genética, Exones/genética, Crizotinib/uso terapéutico, Inhibidores de Proteínas Quinasas/uso terapéutico, Docetaxel/uso terapéutico, Cisplatino/uso terapéutico, Antineoplásicos/uso terapéutico, Neoplasias Pulmonares/tratamiento farmacológico, Adenocarcinoma/tratamiento farmacológico